NON CONSULTABILE SALVO PREVIA RICHIESTA AL DIPLOMANDO) Metodologia di testing per un progetto software di grandi dimensioni

TL;DRAbstract

Blinatumomab (Blincyto) for the treatment of patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia (ALL) General information Drug description [1]Indication [2] Blinatumomab is a bispecific T-cell-engaging antibody construct that binds simultaneously to CD3-positive cytotoxic T cells and CD19-positive B cells and allows endogenous T cells to recognize and eliminate CD19-positive ALL blasts.Blinatumomab is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-precursor ALL.Patients with Philadelphia chromosome positive (Ph+) B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options. Current treatment [3] TKIs are used to treat Ph+ ALL by inhibiting the BCR-ABL protein from sending signals that cause leukaemia cells to form. TKIs are added to a combination chemotherapy regimen; the following TKIs are available to treat Ph+ ALL: Imatin

Chat with Paper

AI Agents for this Paper